THE RISE OF PATENT LITIGATION AND THE BATTLE FOR MARKET EXCLUSIVITY
Intellectual property (IP) disputes, and patent disputes in particular, are an increasingly important class of the Australian legal environment. These disputes have business-critical consequences for major players in the technology, pharmaceutical, mining and engineering sectors. This is especially so in pharmaceutical patent cases, where hundreds of millions of dollars can hang on whether a patent is considered to be valid, and infringed, by a competing product.
Australia is a significant venue for pharmaceutical patent litigation. Often, patent disputes are litigated in Australia before similar disputes arise in other major jurisdictions (such as the US and Europe) due to Australia’s relatively short regulatory data protection regime for pharmaceutical products, which means that generic players can reference the innovator’s product data at an earlier stage to support the bioequivalence of their own ‘copycat’ products.
The space is currently in a state of flux. In the past 18 months, Australia’s Federal Court has recommenced granting preliminary injunctions after a seven-year drought, has invalidated an entire class of term extensions for pharmaceutical patents, and the High Court has heard an appeal (judgment pending) that may require the revaluation of pharmaceutical portfolios across the country. Alternative market access pathways for copycat or compounded products are creating competitive threats that innovator companies never planned for, and the Federal Court has very recently instituted procedural reforms that allow complex pharmaceutical disputes to be resolved far quicker. For a jurisdiction long regarded as a secondary consideration in global patent strategy, Australia has become an unexpectedly active front in the battle for market exclusivity.
Oct-Dec 2026 issue
Clayton Utz